Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 25 Oct 2026
Promising but preliminary

Dapagliflozin improves left ventricular diastolic function and reduces inflammatory cytokines in heart failure with preserved ejection fraction

A common diabetes drug added to heart failure treatment reduces inflammation and improves heart function in a patient group with historically few medication options.

This retrospective cohort study demonstrates that dapagliflozin added to standard therapy improves left ventricular diastolic function and significantly reduces pro-inflammatory cytokines (IL-6, TNF-alpha, hs-CRP) and NT-proBNP in HFpEF patients over six months. The findings provide mechanistic and clinical evidence supporting SGLT2 inhibitor use in HFpEF, a disease with historically limited pharmacological options.

What the study was

Study design
Retrospective cohort study
Category
T7: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
Maturity
Validated
Journal
American Journal of Translational Research

Why it surfaced

HFpEF is a growing epidemic with few proven therapies; this study provides actionable evidence on dapagliflozin anti-inflammatory and diastolic improvement effects supporting near-term clinical implementation aligned with the SGLT2 watchlist focus.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.